Abstracts Archive - Page 468 of 2605 - ACR Meeting Abstracts

Abstract Number: 2560 • ACR Convergence 2023
Risk of Gastrointestinal Perforation Among Patients with Giant Cell Arteritis Who Received Tocilizumab
Desh Nepal¹, Sebastian Sattui², Zachary Wallace³ and Mike Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²University of Pittsburgh, Pittsburgh, PA, ³Massachusetts General Hospital, Newton, MA, ⁴Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Exposure to the interleukin-6 inhibitor tocilizumab has been associated with an increased risk of gastrointestinal (GI) perforation in patients with rheumatoid arthritis. No studies…
Abstract Number: 2546 • ACR Convergence 2023
Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up
CLARISSA PIMENTEL, ANA CRISTINA MEDEIROS-RIBEIRO, ANDREA SHIMABUCO, PERCIVAL SAMPAIO-BARROS, JULIO CESAR MORAES, CLAUDIA SCHAINBERG, CELIO GONÇALVES, ELAINE LEON, LEONARD KUPPA, Sandra Pasoto, NADIA AIKAWA, CLOVIS SILVA, Eloisa Bonfa and CARLA SAAD, University of São Paulo, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) therapies were one of the major advances in the treatment of Ankylosing Spondylitis (AS) patients. For infliximab, anti-drug antibodies…
Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Christoph Berger², Christos Polysopoulos¹, Adrian Ciurea³, Diego Andrey⁴, Tanja Maletic¹, Myriam Riek¹, Almut Scherer¹, Isabell von Loga¹, Judith Safford¹, Kim Lauper⁵, Burkhard Moeller⁶, Nicolas Vuilleumier⁴, Axel Finckh⁷ and Andrea Rubbert-Roth⁸, ¹SCQM Foundation, Zurich, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Zurich, Zürich, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Geneva University Hospitals, Genève, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷HUG, Geneva, Switzerland, ⁸Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…
Abstract Number: 2565 • ACR Convergence 2023
The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021
Titilola Falasinnu¹, Di Lu² and Matthew Baker³, ¹Stanford School of Medicine, Palo Alto, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford University, Menlo Park, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are salient causes of disability, functional limitations, reduced quality of…
Abstract Number: 2562 • ACR Convergence 2023
Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study
Adrien Cottu¹, Alessandro Tomelleri², Corrado Campochiaro³, Alexandra Forestier⁴, Jérémie Dion⁵, Milena Bond⁶, Ariane Laparra-ramakichenin⁷, Aline Gury⁸, Xavier Savary⁹, Robin Dhote¹⁰, Albrecht Betrains¹¹, Laurence Bouillet¹², Eric Liozon¹³, Eva Bories¹⁴, Arthur Petitdemange¹, Paul Legendre¹⁵, Benjamin Crichi¹⁶, Philippe Kerschen¹⁷, Lucie Carneiro-Esteves¹⁸, Lucile Grange¹⁸ and Benjamin Terrier¹⁹, ¹Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁴Department of Medical Oncology, Centre Oscar Lambret, Lille, France, ⁵Internal Medicine Department, Toulouse University Hospital, Toulouse, France, ⁶Azienda sanitaria dell'Alto Adige, Merano, Italy, ⁷Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France, ⁸Department of Internal Medicine, Arras GHAT, Arras, France, ⁹Department of Internal Medicine, Brest CHU Hospital, Brest, France, ¹⁰Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, ¹¹Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹²Internal medicine department, Grenoble University Hospital, Grenoble, France, ¹³Department of Internal Medicine, University Hospital of Limoges, Limoges Cedex, Limoges, France, ¹⁴Department of Internal Medicine, Purpan CHU Hospital, Toulouse, France, ¹⁵Department of Clinical Immunology, Centre hospitalier du Mans, Le Mans, France, ¹⁶Department of Internal Medicine, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ¹⁷Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, ¹⁸Department of Internal Medicine, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France, ¹⁹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis for many cancers. The therapeutic effect of ICIs is based on their ability to release…
Abstract Number: 2561 • ACR Convergence 2023
The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group
Alessandro Tomelleri¹, Corrado Campochiaro², Francesco Muratore³, Sara Monti⁴, Nicola Farina⁵, Chiara Marvisi⁶, Elena Galli⁷, Alessandra Milanesi⁸, Naomi Viapiana⁵, Alvise Berti⁹, Roberto Bortolotti⁹, Milena Bond¹⁰, Roberto Padoan¹¹, Mara Felicetti⁹, Franco Schiavon¹², Carlotta Nannini¹³, Fabrizio Cantini¹³, Alessandro Giollo¹⁴, Maurizio Rossini¹⁵, Edoardo Conticini¹⁶, Bruno Frediani¹⁷, Fabrizio Conti¹⁸, Roberta Priori¹⁸, Marco Sebastiani¹⁹, Giulia Cassone²⁰, Luca Quartuccio Quartuccio²¹, Elena Treppo²², Silvano Bettio²³, Ariela Hoxha²⁴, Marco Lovisotto²⁴, Giacomo Emmi²⁵, irene mattioli²⁶, Pietro Leccese²⁷, Roberto F. Caporali²⁸, Lorenza Maria Argolini²⁹, Rosario Foti³⁰, Elisa Visalli³⁰, Michele Colaci³¹, Carlomaurizio Montecucco³², Lorenzo Dagna³³ and Carlo Salvarani³⁴, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁵IRCCS San Raffaele Hospital, Milan, Italy, ⁶IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁷Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁸Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁹Santa Chiara Hospital of Trento, Trento, Italy, ¹⁰Azienda sanitaria dell'Alto Adige, Merano, Italy, ¹¹Department of Medicine DIMED, University of Padova, Padova, Italy, ¹²University of Padova, Padova, Italy, ¹³Santo Stefano Hospital Prato, Prato, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁵Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ¹⁶Tallaght University Hospital, Dublin, Ireland, ¹⁷University of Siena, Siena, Italy, ¹⁸University of Rome La Sapienza, Rome, Italy, ¹⁹Azienda Policlinico di Modena, Modena, Italy, ²⁰University of Modena and Reggio Emilia, Modena, Italy, ²¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²²Physician, Moimacco, Italy, ²³University of Padua, Treviso, Italy, ²⁴San Bortolo Hospital of Vicenza, Vicenza, Italy, ²⁵University of Florence, Florence, Italy, ²⁶University of Florence, Firenze, Italy, ²⁷Regional Hospital San Carlo, Potenza, Italy, ²⁸Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ²⁹ASST Gaetano Pini, Milano, Italy, ³⁰AOU San Marco, Catania, Catania, Italy, Catania, Italy, ³¹University of Catania, Catania, Italy, ³²Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy, ³³Ospedale San Raffaele, Milano, Italy, ³⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The 2022 classification criteria for giant cell arteritis (GCA) have been recently published. The aim of this study is to investigate whether the score…
Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Jinqi Liu¹, Yicong Li², Kai Fu¹, Chun Wu¹, Peter Schafer³, Sean Connolly¹, Ian M. Catlett⁴, Michael Maldonado¹, Robert Wong⁵, Paul Emery⁶, Yoshiya Tanaka⁷, Vivian Bykerk⁸, Clifton Bingham⁹, Thomas Huizinga¹⁰ and Roy Fleischmann¹¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Parexel International, Durham, NC, ³Bristol Myers Squibb, Belle Mead, NJ, ⁴Bristol Myers Squibb, Pennington, NJ, ⁵Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
Abstract Number: 2563 • ACR Convergence 2023
Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study
Ying Hu¹, Hongyi He², Yuqing Zhang³, Houchen Lyu⁴, Chao Zeng², Jie Wei⁵ and Guanghua Lei², ¹Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China, ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Chinese PLA General Hospital, Department of Orthopedics, Beijing, China, ⁵Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Gut microbiota has been increasingly recognized as important and novel targets for rheumatic diseases. However, previous studies mostly examined the associations, leaving causality largely…
Abstract Number: 2556 • ACR Convergence 2023
End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
Jiacai Cho¹, Liang Shen², Rangi Kandane-Rathnayake³, Vera Golder³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yeong-Jian J Wu⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhuoli Zhang¹⁴, BMDB Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Shereen Oon²⁰, Sean O’Neill²¹, Fiona Goldblatt²², Kristine Ng²³, Annie Law²⁴, Nicola Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra⁹, Chak Sing Lau²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹, Eric Morand³² and Aisha Lateef³³, ¹National University Hospital, Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Taichung Veterans General Hospital, Taichung, Taiwan, ⁶Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Peking University People’s Hospital, Beijing, China, ¹¹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ¹⁶Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁷Keio University, Keio, Japan, ¹⁸Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²⁰Department of Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²¹Department of Medicine, University of New South Wales, Kensington, Australia, ²²Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²³Waitemata DHB, Auckland, New Zealand, ²⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²⁵Auckland District Health Board, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Manila, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ³²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³³National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore
Background/Purpose: SLE patients suffer high symptom burden at the end-of-life. However, the course of disease and treatment burden in the last year of life have…
Abstract Number: 2549 • ACR Convergence 2023
Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
Walter P. Maksymowych¹, Robert Lambert², Eswar Krishnan³, Baojin Zhu³, Rebecca Bolce³ and Mikkel Østergaard⁴, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The effect of Ixekizumab (IXE) on structural lesions in the sacroiliac joints (SIJ) of patients (pts) with radiographic Axial Spondylarthritis (r-axSpA) assessed by magnetic…
Abstract Number: 2508 • ACR Convergence 2023
Chronic IL-6 Trans-Signaling Enhances Stem Cell-Like Characteristics of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: Chronic exposure to IL-6 trans-signaling has been shown to significantly impact the characteristics of rheumatoid arthritis synovial fibroblasts (RASFs). Previous studies have demonstrated that…
Abstract Number: 2413 • ACR Convergence 2023
Janus Kinase Inhibitors in Giant Cell Arteritis in Clinical Practice. Real-World Clinical Practice Study and Literature Review
Fernando López¹, Javier Loricera², Toluwalase Tofade³, Diana Prieto-Peña², Susana Romero Yuste⁴, Eugenio De Miguel⁵, Anne Riveros-Frutos⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸, Eztizen Labrador-Sánchez⁹, Olga Maiz¹⁰, Elena Becerra-Fernández¹¹, Javier Narvaez¹², Eva Galindez-Agirregoikoa¹³, Ismael González¹⁴, Ana Urruticoechea¹⁵, Sebastian Unizony¹⁶ and Ricardo Blanco¹⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Neurology Department, Massachusetts General Hospital, Boston, MA, ⁴Complexo Hospitalario Universitario, Pontevedra, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital Universitario San Pedro, Laguardia, Spain, ¹⁰Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Torrevieja, London, United Kingdom, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Hospital Universitario de León, León, Spain, ¹⁵Hospital Can Misses, Ibiza, Spain, ¹⁶Massachusetts General Hospital, Winchester, MA, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with giant cell arteritis (GCA) can relapse despite glucocorticoids, methotrexate and tocilizumab treatment. The JAK/STAT signalling pathway is involved in the pathogenesis of…
Abstract Number: 2420 • ACR Convergence 2023
Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez², Javier Narvaez³, Noemi Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula V. Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maria. T Silva-Diaz⁸, Joaquín M. Belzunegui⁹, Clara Moriano Morales¹⁰, Julio Sanchez Martin¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro¹³, lydia Abasolo¹⁴, Javier Loricera¹¹, Patricia Moya¹⁵, Maria J. García-Villanueva¹⁶, Carles Galisteo¹⁷, Anne Riveros-Frutos¹⁸, Francisco Ortiz-Sanjuán¹⁹, Selene Labrada-Arrabal²⁰, Margarida Rocha²¹, Carlos García-Porrúa²², Maria García-González²³, Clara Molina Almela²⁴, María Alcalde²⁵, Antonio Juan Mas²⁶, Fernando Alonso²⁷, Santos Castañeda²⁸, Ricardo Blanco²⁹ and on behalf of the Collaborative Group members³⁰, ¹Hospital de Mérida, Merida, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, Donostia, Spain, ¹⁰Rheumatology, Hospital Universitario de León, León, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Basurto University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴Hospital Clínico San Carlos, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ¹⁹Hospital Universitario y Politécnico La Fe, Valencia, Spain, ²⁰Hospital del Mar, Barcelona, Spain, ²¹Osakidetza, Bilbo, Spain, ²²Hospital Universitario Lucus Augusti, Lugo, Spain, ²³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁴Hospital General de Valencia, Valencia, Spain, ²⁵Hospital Severo Ochoa, Madrid, Spain, ²⁶Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁷Spanish Society of Rheumatology, Madrid, Spain, ²⁸Hospital Universitario de la Princesa, Madrid, Spain, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰ARTESER group, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in North America and Western Europe. GCA is more likely to occur in women (1).…
Abstract Number: 2050 • ACR Convergence 2023
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Randal De Souza¹, Merav Heshin Bekenstein², Beth Rutstein³, Maria Schletzbaum⁴, Nora Singer⁵, Melanie Kohlheim⁶, vincent del gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock¹⁰, Rebecca Sadun¹¹, Monica Ardura¹, Vidya Sivaraman¹ and For The CARRA Registry Investgators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Dana Children's Hospital of Tel Aviv Medical Center, Tel Aviv, Israel, ³Division of Rheumatology at Children's Hospital of Philadelphia, Philadelphia, PA, ⁴St. Louis Children’s Hospital / Washington University in St. Louis, Middleton, WI, ⁵The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Self, Granville, OH, ⁷CARRA, Inc, Washington, DC, ⁸Nationwide Children's Hospital, Hilliard, OH, ⁹Ohio State University, Columbus, OH, ¹⁰Dept. of Biomedical Informatics, Columbus, OH, ¹¹Duke University, Durham, NC
Background/Purpose: Immunocompromised children (ICC), including children with rheumatic diseases receiving immunosuppressive therapies (IST) are at increased risk of morbidity from vaccine-preventable infections. The 2022 American…
Abstract Number: 0310 • ACR Convergence 2023
Implementing an Osteoarthritis Management Program to Deliver Guideline-Driven Care for Knee and Hip Osteoarthritis in a U.S. Academic Health System
Kathryn Miller¹, Divya Vundamati², Linda Baier¹, Roger Brown¹, Tommy Yue Yu¹ and Christie M. Bartels³, ¹University of Wisconsin, Madison, WI, ²UW Health, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: To assess patient outcomes from an Osteoarthritis Management Program (OAMP) situated in an academic medical center.Methods: Eligibility for this open cohort study included adults…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].